Remarkably, these findings showed significant improvement over conventional clinical analysis of the tumor markers cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA) and tissue polypeptide antigen (TPA) for breast cancer monitoring, which have only at most 60–70% of sensitivity and specificity [8,9,49]. This evidence concerns the gene PLAT and neoplasm.